Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone spends a hundred buck to get stock back over 16 cents. Wonder who that could be? Wink, wink, nod, nod.
$.072 new all time low. Sevens on the seventh. Guess we got below a dime even quicker than I thought.
And you thought GNBP was a PUBLIC company. Someone go find Tony Cataldo and Mike Handelman and tell them to make 10Q filing and tell stockholders what is going on. You don't want a replay of Tony's actions at VOIC, MTCH, and GSTY do you?
Below is an article posted on www.seekingalpha.com about GNBP, Tony Cataldo, and Mike Handelman written by Isaac Silbermann on 12-7-2011 (about 13 months ago) when GNBP stock was selling at $ 1.12 a share.
Isaac sure got this one right, didn't he?
-------------------------------------------------------------
Disclosure: I am short GNBP.OB. I receive no compensation to write about any specific stock, sector or theme.
Investing in biotech stocks is usually a risky proposition. First of all, investors rarely have the scientific background to evaluate the claims of most of the potential products being researched. Additionally, there is always the chance that a product being researched fails a key clinical test, in which case, the affected company’s stock will usually experience significant losses. Furthermore, because of the nature of biotech companies, they usually do not generate significant revenue during their research phase, although they do experience operating costs associated with the research.
With this in mind, when investing in biotech stocks, it is particularly important to evaluate the strength of management and the cost structure of the company itself. Investing in a company with suspect management or poor financial stewardship is questionable at the best of times, but particularly so for biotech companies because of their lack of tangible assets and negative cash flows. When assessing biotech stocks, potential investors should always critically evaluate several key points: Does the company have a sufficient war-chest to see it through the various regulatory hurdles necessary to realize value for shareholders? Does management have a relevant scientific background or history of successful start-ups? Most biotechs have large addressable markets, so the specific area of research under study often should be secondary to these questions.
Today I will present Part 1 of a series examining Genesis Biopharma (GNBP.OB) and why this is exactly the type of biotech company that investors should avoid. In today’s piece I will examine GNBP’s management team, CEO Anthony Cataldo and CFO Michael Handelman and the long list of failed public companies under their management or directorship. I will also look at Genesis’ own similarity to management’s other failed enterprises and its history of paid stock promotion.
CEO Anthony Cataldo’s Suspicious History of Failed, Heavily Promoted Companies
Genesis Biopharma’s CEO Anthony Cataldo has been involved in many public companies over the last decade, including some where he continues to serve in an executive capacity. This should be the first red-flag to investors. A truly committed executive may be involved as a board member of multiple companies, but if a CEO is also serving as an officer for multiple companies, he clearly cannot be devoting his full attention to any one of them. The details of Mr. Cataldo’s corporate associations are outlined in GNBP’s 2010 10-K:
Mr. Cataldo currently serves as the Chairman, Chief Executive Officer and a Director of Oxis International, Inc. (“Oxis”), a position that he has held since March 2009. Oxis is a public company engaged in the research, development and sale of products that counteract the harmful effects of “oxidative stress.” Mr. Cataldo served as Chief Executive Officer and Chairman of the Board of VoIP, Inc., a public company and provider of Voice over Internet Protocol (VoIP) communications, from September 2006 through April 2008. Mr. Cataldo currently also is the Chief Executive Officer and Chairman of the Board of Green St. Energy, Inc., a public company that intends to enter the alternative energy business. Mr. Cataldo joined Green St. Energy, Inc, in September 2008. From October 2003 through August 2006, Mr. Cataldo has served as non-executive Chairman of the Board of Directors of Brand Partners Group, Inc., a public company provider of integrated products and services dedicated to providing financial services and traditional retail clients with turn-key environmental solutions. Mr. Cataldo also served as non-executive Co-Chairman of the board of MultiCell Technologies, Inc., a public company supplier of functional, non-tumorigenic immortalized human hepatocytes, from February 2005 through July 2006. Mr. Cataldo has also served as Executive Chairman of Calypte Biomedical Corporation, a publicly traded biotechnology company, involved in the development and sale of urine based HIV-1 screening tests from May 2002 through November 2004. Prior to that, Mr. Cataldo served as the Chief Executive Officer and Chairman of the Board of Directors of Miracle Entertainment, Inc., a Canadian film production company, from May 1999 through May 2002 where he was the Executive Producer or Producer of several motion pictures. From August 1995 to December 1998, Mr. Cataldo served as President and Chairman of the Board of Senetek, PLC, a publicly traded biotechnology company involved in age-related therapies.
As one can see from his resume, although he has some biotech experience, the majority of the companies that Mr. Cataldo has been involved in do not share a common industry or area of focus. What they do all share are suspicious stock charts indicative of “Pump and Dump” schemes: sharp spikes in share price followed by dramatic and sustained declines into penny-stock oblivion. Many of them also share another key feature of Pump and Dump schemes, the use of paid stock promoters.
At Oxis International (OXIS.OB), we can see from page 38 of their 2010 10-K that Mr. Cataldo receives a generous cash salary of $180,000, in addition to significant stock-based compensation. This is despite the fact that during that year, the company had no significant sales, incurred losses of almost $3 million and spent only $179,000 on research and development. The fact that OXIS, which is ostensibly in the business of “developing and marketing nutraceutical products in the field of oxidative stress reduction”, spent less on R&D than on the cash component of Mr. Cataldo’s compensation should be a clear indication to all just how serious this company is about actually developing and marketing the aforementioned products. On the other hand, OXIS has definitely been serious about spending money for paid stock shills to promote their stock.
One such example from paid stock promoter Eric Dickson can be viewed here. Note the disclaimer:
Oxis International Inc., (OXIS), the company featured in this issue, appears as paid advertising, paid by Oxis International Inc. to provide public awareness for OXIS…CFM has received and managed a total production budget of $300,000 for this online advertising effort.
The stock chart of OXIS during Mr. Cataldo’s tenure shows ominous signs of a Pump and Dump with the stock spiking to over $0.60 on the back of the stock promotion campaign, soon experiencing a significant and sustained decline to $0.04 where it sits today, a loss of over 90%.
click to enlarge
A corporate association of Mr. Cataldo’s not listed by Genesis Biopharma is Matech Corp. (MTCH.PK), a now-defunct company where according to an 8-K, Mr. Cataldo has served as executive-chairman since September 9, 2009. As of the company’s last filing with the SEC on July 19, 2010, Cataldo held the position of President and CEO. Although the company had no significant business operations, was serially delinquent in filing with the SEC and had significant legal and financial liabilities, MTCH’s stock was nonetheless the subject of a significant promotional campaign just several months after Mr. Cataldo entered the picture.
Again, note the disclaimer: “Hototc.com has been compensated by a third party Serendipity Management one hundred thousand dollars for a one week MTCH advertising services contract.” A look at the stock chart for MTCH during the time when Mr. Cataldo was serving at the company shows all the tell-tale signs of a Pump and Dump. The company now trades for $0.001/share, a loss of over 99% since Mr. Cataldo got involved.
Another of Anthony Cataldo’s companies which ended disastrously for shareholders was VoIP Inc. That company’s business focus was ostensibly to provide voice-over-IP telecommunications solutions and they even supposedly inked a deal of partnership with Google. Alas, despite management’s puffery regarding this deal, the company eventually ended up bankrupt and targeted by the SEC for allegedly engaging in fraud.
During Cataldo’s tenure as the CEO of VoIP, the company hired a shady stock promoter, CEOcast, to tout the stock, as evidenced here. The disclaimer reveals that CEO cast was paid “ten thousand dollars per month and three hundred fifty thousand shares of stock” for a 1 year promotional program. CEOcast is a paid stock shill service reportedly run by a convicted felon, details of which can be found here and here. Trading in VoIP’s stock was halted and it is no longer listed on any exchange; thus shareholders in this Cataldo company wound up losing 100% of their investment.
I believe that the 3 examples highlighted above illustrate a consistent pattern with companies under Anthony Cataldo’s stewardship: negligible business operations with major operating losses and serious stock promotion. I will not examine all of Cataldo’s other corporate associations in depth, however, a picture is worth a thousand words, so below are charts of some of Cataldo’s other corporate associations during his tenure with each.
Green St. Energy
Brand Partners
Multicell Technologies
Calypte Biomedical
CFO Michael Handleman’s Corporate History is Also Suspect
Anthony Cataldo isn’t the only executive at Genesis with a dodgy past; from GNBP’s 2010 10-K we can also gain some insight into the history of its CFO, Michael Handelman:
Mr. Handelman was appointed to the positions of Secretary, Treasurer, Chief Financial Officer and Director on February 7, 2011. Mr. Handelman is currently the Chief Financial Officer of Oxis International, Inc., a position that he has held since March 1, 2010. Mr. Handelman was a financial management consultant to Oxis from August 2009 until March 2010. Before joining Oxis, from November 2004 until July 2009, Mr. Handelman served as Chief Financial Officer and Chief Operating Officer of TechnoConcepts, Inc., a developing technology and manufacturing company. Prior to that, Mr. Handelman served from October 2002 to October 2004 as Chief Financial Officer of Interglobal Waste Management, Inc., a California start-up manufacturing company, and from July 1999 to September 2002 as Vice President and Chief Financial Officer of Janex International, a children’s toy manufacturer. Mr. Handelman has also been the Chief Financial Officer from 1993 to 1996 of the Los Angeles Kings, a National Hockey League franchise.
Los Angeles Kings aside, most of Michael Mandelman’s other corporate associations are with now-defunct companies trading on the OTCBB or Pink Sheets. OXIS, of which Handelman is the CFO, was covered earlier since Anthony Cataldo is also the CEO of that company. Let’s take a brief look at Mr. Mandelman’s other recent association, TechnoConcepts Inc. (TCPS.PK). Mr. Mandelman’s tenure at TechnoConcepts is notable in that he oversaw the company’s stock price collapse from over $5/share to the $0.001/share level it sits at today. TechnoConcepts was a California-based company that according to its most recent 10-K was:
In the process of attempting to commercialize proprietary technology that we refer to as True Software Radio™. True Software Radio™ is an advanced delta-sigma microchip architecture that converts radio frequency, or RF, signals directly into digital data. TechnoConcepts also owns a controlling interest in Asanté Networks Inc., based in San Jose, California. Asanté provides Ethernet networking solutions for Apple Computer and the small-to-medium business retail markets.
As outlined in the 10-K, Mr. Mandelman received a pay package of $127,500 in 2006 from TCPS which seems quite generous considering that the company was a serial delinquent in terms of filing its SEC financials, forced to restate its financials for the years 2005 and 2004 and had just over $800,000 in total gross profit in 2006. In 2007, the company seems to have imploded based on a reading of its position of outstanding liabilities vs. assets and the collapsing sales results in the final 10-Q filed with the SEC.
At the end of 2007, the company filed an NT 10-K indicating that it would be late in filing its 10-K for the year. After that, without any specific explanation, the company simply stopped filing statements with the SEC and the stock took a final nosedive from about $0.25/share to the sub-penny level where it remains today. Below is a stock chart of TCPS during Mr. Mandelman’s tenure with the company.
The TCPS 2006 10-K yields a bit more information about Mr. Mandelman’s corporate associations. Apparently the same Interglobal Waste Management outlined by GNBP was actually a public company, and he was also "chief financial officer and chief operating officer of Global Business Services, Inc., a publicly traded retail postal and business services company.” Interglobal Waste Management traded under the stock symbol IGWM, but never filed much in the way of financials with the SEC beyond an original prospectus. Based on their 2004 10-K, it seems as though Michael Handelman served as the CFO of Global Business Services from February 2003 to July 2004. That company would later go defunct and become a shell company that merged into Pavilion Energy Resources in 2008.
Genesis Biopharma: The More Things Change, The More They Stay The Same
Genesis Biopharma, Anthony Cataldo and Michael Mandelman’s latest company bears a striking resemblance to their earlier corporate associations. As one can see looking at the most recent 10-Q, Genesis has no revenues, significant operating losses, poor cash-to-current liabilities position and a pie-in-the-sky vision - a cure for skin cancer in this case. Page 22 also outlines another similarity, generous annual compensation packages for Mr. Cataldo and Mr. Handleman of $300,000 and $120,000, respectively, in addition to stock based compensation.
Genesis Biopharma also resembles Mr. Cataldo’s other companies with regard to its use of paid stock shills to support GNBP’s stock price. Genesis paid an infamous stock promoter, Jarrett Wollstein, to produce a promotional piece touting their stock and the 500% upside that would be realized based on an imagined bidding war by “Big Pharma”. These promotional pieces can be found here and here. Wollstein is sneaky and does not include his disclaimer on the main page of these promotional pieces, but it can be found here. Note the disclaimer:
Intelligent Investor Report received an editorial fee of twelve thousand dollars from Gulfstream Business Group (GBG), which it received from GNBP. GNBP was chosen to be profiled after Intelligent Investor Report completed due diligence on the company…GBG paid fifteen thousand, eight hundred dollars, which it received from GNBP, to advertising agencies for the costs of creating and distributing this report online, in an effort to build investor awareness. GBG paid Ray Dirks twenty-five thousand dollars from the total GNBP budget for reprint and distribution rights of Ray Dirks Research report on GNBP. GBG was paid a fee of one hundred thousand dollars pursuant to a consulting agreement with GNBP.
Conclusion
It has been said that the definition of insanity is doing the same thing over and over and expecting different results. This quote seems particularly apt when looking at a company like Genesis Biopharma. Can shareholders truly expect that in the end GNBP really will find that pot of gold at the end of the clinical research rainbow and discover a significant new cancer treatment? Given management’s extensive history of stock promotion and the disastrous results experienced by shareholders of their other companies, it seems highly unlikely that GNBP shareholders will be presented with this happy ending. What seems much more plausible is that GNBP will end up exactly where those other companies did, experiencing 90%+ equity losses or else completely defunct.
Part 2 of this report will examine the state of the Genesis Biopharma today, in terms of its unsustainable cost structure and recent shift in research focus. I will chronicle GNBP’s corporate history as well as its history of dubious financial transactions. I will explain how thanks to an ill-advised convertible debt deal with a long-time Cataldo crony, GNBP now faces the possibility of imminent bankruptcy or major unforeseen dilution. Finally, I will present additional supporting evidence that Genesis Biopharma is being used as a vehicle for a "Pump and Dump” scheme.
--------------------------------------------------------------
If Isaac shorted this all the way down from $ 1.12 to present $ .15, he had a great 2012 in GNBP stock.
We are still waiting for part 2. Its probably not necessary at this point.
Wonder if Bristol, Theorem, and Ayers have decided to cut their losses here at GNBP?
Stock climbs 2 cents to $ .15 in last two minutes of paint the tape trading.
Rewally pathetic that this only gets a $ .15 stock price."
Stock now down to $.13 and that's the ask price. Bid is $.055.
Ouch
Tomorrow 1-4-2013 will mark one month since we last heard from Tony Cataldo. On 12-4-2012 Tony announced in an 8K that the Chairman Hans Bishop had resigned in late November.
Since then not a peep from Tony.
No word on the 7-8 million in debt which is now all past due as per filings on record. No word on getting filings current. no word on replacemnt for Hans. No word of $ 250,000 CRADA payment being made in December.
Tony "No Telling" Cataldo at work.
Tony Cataldo = Unbelievable
If we get no further news or filings in January from Tony or Mike, I predict a record low $ .10 - $ .15 stock price by February 1, 2013.
If we get "the whole truth and nothing but the truth" about GNBP in January the stock price could be even lower.
IMO of course, lets see how it plays out.
Tony Cataldo January 2013 to do list?
1. Type up new resume.
2. Check with Paul Kessler, Andy Dube, Martin Schroeder, Merrill McPeak, and David Dadon to see what my next "move" will be.
3. Prepare for my 62nd birthday. Perhaps having it on the Queen Mary and having my band "Chicago" play would be appropriate.
4. Perhaps a new Money TV interview?
1-2-2013, Outstanding GNBP items from 2012.
1. Put out 10Q for third quarter that was initially due 11-14-2012.
2. Pay off 1.4 plus million due to lenders on 12-31-2012 who hold all of GNBP's assets as well as all of Tony Cataldo's GNBP stock as collateral.
3. Pay off lenders 5.2 million due 11-30-2012.
4. Pay off $ 616,000 due to NIH.
5. Pay $ 250,000 December CRADA payment.
6. Catch up payments to directors, advisors, and consultants.
7. Find money to continue forward with GNBP knowing that any income is years away.
Well as we exit 2012 and head into 2013, lets analyze the last quarter of 2012 here at GNBP.
Number of SEC filings = 4
Number of paid hype "ïnterviews" at Money TV = 5
SEC filings
8K in early October announcing that 1.481 Million owed to 13 ïndividuals against all assets of company had been extended from 9-30-2012 to 12-31-2012.
8K in mid October announcing a $ 250,000 loan made to GNBP on September 12, 2012. (Probably to pay $ 250,000 quarterly CRADA payment due in September)
10QNT filed 11-13-2012 saying 10Q for third quarter 2012 due 11-14-2012 would be delayed by 5 calendar days.
8K in early December announcing the resignation of Hans Bishop as Chariman of the Board.
Please note the promised 10Q has still not been filed.
MONEY TV "ïnterviews"
5 paid for interviews, cost somewhere between $ 11,000 and $ 17,000 starring Tony Cataldo regaling GNBP. Last interview on 11-16-2012 just before failure to file 10Q in 5 calendar days as promised.
Welcome to "Cataldoland".
This is so similar to his actions at MTCH in 2009-2010 that it is scary.
GNBP a failure? I don't know . Tony lists most of his companies on his "resume" when he moves to a new company and in my opinion they were pretty much all failures.
Definitely scenario 2.
GNBP will always be remembered as a failure...from Tony's POV.
Tony Cataldo's to do list for 12-31-2012.
1. Put out 10Q for third quarter that was initially due 11-14-2012.
2. Pay off 1.4 plus million due to lenders on 12-31-2012 who hold all of GNBP's assets as well as all of Tony Cataldo's GNBP stock as collateral.
3. Pay off lenders 5.2 million due 11-30-2012.
4. Pay off $ 616,000 due to NIH.
5. Pay $ 250,000 December CRADA payment.
6. Catch up payments to directors, advisors, and consultants.
7. Find money to continue forward with GNBP knowing that any income is years away.
or
1. Type up new resume
2. Check with Paul Kessler, Andy Dube, Martin Schroeder, and Merrill McPeak to see what my next "move" will be.
3. Get ready for a fantastic New Years Eve welcoming in an odd numbered year (2013) where my luck has been much better than even numbered years.
I believe scenario number 2 will be closer to the truth. But I would LOVE to be proven wrong by Tony.
So, a manufactured January effect?
Maybe I will have to apologize to Tony Cataldo and Mike Handelman for not getting the 10Q out before now.
Maybe with all that is going on, with the Chairman resigning, the $ 616,000 overdue to NIH, the $ 250,000 December CRADA payment, the 5.2 million plus due lenders on 11-30-2012 and the 1.4 million plus due to lenders on Monday (12-31-2012), that Tony and Mike have been securing a new Chairman and have been working with new lenders and investors brought in by the Money TV interviews to clear up all debt and as Tony said in the Money interview, paving a way to get GNBP onto a major stock exchange. With all that happening, its possible that the 10Q has been delayed so that Tony can make the 10Q filing in early January announcing all the wonderful news of a new Chairman and debt resolution in the subsequent events section of the 10Q.
Or it could be a replay of MTCH where Tony didn't announce debt default of 12-31-2009 until summer of 2010, when he told everyone the company asssets had been turned over to lenders and company had shut down(after filing 10QNT in April 2010 and failing to file 10K).
Guess we will know shortly.
$.1525 at close. Is this a new low for a GNBP close?
Tony "record setting" Cataldo at work.
Or perhaps its the three monkeys "see no evil, hear no evil, speak no evil" strategy.
looks like Tony and Mike are going for the ostrich "head in the sand" strategy with GNBP
Alrighty lets get this baby off the ground:
Tony's check list:
1. More Money TV puff interviews (No questions about filings or past due debts allowed)
2. Need $ 250,000 for December CRADA
3. Find a new Chairman of The Board to replace Hans Bishop.
4. Extend all other debt payments (about 7 million dollars worth) another 6 months.
Note to self: Meet with Paul to discuss next business venture.
Will the shareholders find a GNBP 10Q in their stockings on Wednesday?
Or will it be Cataldo coal?
GNBP up 3.01 cents a share in todays trading, to $ .19 a share.
Now you can only get 5 shares for a buck with a nickel left over.
Will wonders ever cease?
Hey Tony and Mile how about a 10Q Christmas present, It's only 40 days past due.
Well its the end of the year. Is it time to take your tax loss here at GNBP run by Tony "Tax Loss" Cataldo?
Lets hope all your funds were not invested in Cataldo run companies , as there would be no gains to offset with losses,
Cataldo special: 6 shares of GNNP for a buck and get 4 cents change.
OK Tony and Mike, The world didn't end yesterday, so back to work, Lets see that extremely delinquent (more than 30 days past due) 10Q.
A year ago on 12/20/2011 GNBP was trading at $ 1.00.
Fridays close $ .1599. So GNBP is down 84% in last year.
and this is not even close to being a record percentage price drop in a year for a Tony Cataldo led company.
It is what it is.
GNBP: joining Tony's list of "we will tell you what we want you to know, when we want you to know it" companies
Is this the "End of Days" for Tony Cataldo.
Will GNBP be "Cataldo's Last Stand".
Will Tony tell Ines that her 3.5 million free shares worth about 5 million in summer of 2011 are now worth about $ 560,000.
Will Tony's landlord Paul, facing large losses here, RXPC, and possibly Mosquito and MILL have to raise the rent on Tony's home?
Stock price about 14 pennies now. Down 1/3 today... any wonder?
The Cataldo "pattern".
Tony Cataldo Leadership:
GNBP trading at just over 21 cents. No longer in compliance with with SEC filing rules. Only thing we have heard from Tony Cataldo or Mike Handelman in last month is that Chairman Hans Bishop has resigned. Millions in debt past due, zero income, only info from "puff" paid hype site Money TV.
and this is the best of the bunch.
No other Cataldo led company is trading at more than a penny a share.
MEMI, CBMC, BPTR, MCET, VOIC, GSTY, MTCH, and OXIS.
"Here's your sign!"
my post 10 days ago
Which will come first Tony Cataldo filing the GNBP 10Q or the Mayan calendar end of 12-21-2012?
Well I guess we got our answer.
I wonder if Tony "Mr. Mendacity" Cataldo and his co-hort Michael "Pants On Fire" Handelman will ever tell us why they lied about filing the 10Q by 11-19-2012?
Just saying .............
One more day when Cataldo fails to perform.
What else is new?
Total trades 100 shares for $ 21.44 total. Way to go Tony.
$.16 now .... You reckon folks are starting to notice that Chairman Hans Bishop has left and CEO Tony Cataldo and CFO Michael Handelman seem to have gone "dark" themselves.
Tony just can't seem to "get it up". Yeah its now about a month past due. 4 plus weeks and counting waiting for Tony to "get it up".
Thats OK Tony, We know there is a lot on your mind. All those debts due, the Chairman resigning, just the stress of trying to keep up with everyone who is pressuring you for results. It can really get to a man. And when you are 61 almost 62 and all these pressures are on you its just difficult to perform.
It can happen to anyone Tony, take it in stride. Its not like anyone is going to replace you here (I don't think anyway).
We are talking about the 10Q. In the past Tony has had troubles filing the annual audited 10Ks (see VOIC, GSTY, and MTCH) but he has usually been good about getting the 10Qs (the non-audited quarterly statements) done on time or at least within the 5 day grace period.
Come on Tony we know you can do it ... can't you?
Except for filing the 8K announcing the resignation of Chairman Hans Bishop we have not heard from CEO Anthony J. "Tony" Cataldo or CFO Michael Handelman for 4 weeks,
4 weeks ago Tony gave a phone interview to Money TV
and one month ago
Michael Handelman filed the 10Q NT which said the 10Q would be late but would be filed within 5 days of the normal due date, or by 11-19-2012.
Couple of real "charmers" heading up this company, don't you think?
Maybe they are devout believers of Mayan dieties and don't see the sense of doing anything in this last week of time with the world ending on 12-21-2012.
My guesses as to situation at GNBP which has led to 10Q not being filed yet:
1. The $ 616,000 owed NIH by 8-27-2012 has not been paid.
2. The 5.2 million owed lenders by 11-30-2012 (after being delayed a year) has not been paid.
3. There is very little cash in bank.
4. Chairman of the Board Hans Bishop was not paid and left.
5. GNBP has not yet found the $ 250,000 necessary to pay the December CRADA payment.
6. The lenders who are owed about 1.5 million against all the assets of GNBP and all of Tony's personal GNBP stock by no later than 12-31-2012 are having heated discussions with
A. Lenders of 5.2 million due 11-30-2012, if they are not the same people.
B. Tony Cataldo and wife Ines Cataldo owner of 2 million and 3.5 million shares respectively of GNBP stock.
C. NIH who wants payment
D. Dr. Rosenberg (CRADA) who wants payment.
E. Lender of last $ 250,000 announced in early October
F. Directors, advisors, and consultants owed their "fees".
But thats just one man's guess as to the situation here at GNBP.
Based on a 10 year observation of Tony "Mr. Wonderful" Cataldo.
Tony could clear up all this with the 10Q filing. Maybe he will.
Tony "No Show" Cataldo fails to produce yet again. 12-12-12
Will THIS be Tony Cataldo's next stop?
Meet Your New Reality TV Stars: Start Engine Announces Its First Class Of Startups
Tuesday, January 10th, 2012, Start Engine, the L.A.-based accelerator that’s the focus of a new reality TV show, is announcing its first round of startups. The show, which comes from Cameron Casey, exec producer of the TechStars reality program on Bloomberg TV, will again film entrepreneurs in a documentary-style format as they make their way through a tech accelerator program.
Start Engine, the incubator founded by Howard Marks, co-founder of Activision, and investor Paul Kessler, founder of the Los Angeles Film School, partnered with the show’s producers in the hopes that the new series will bring increased visibility to the participating companies. The rapid accelerator offers four 90-day cycles per year, each culminating in the nerve-wracking Demo Day events, where the founders pitch a roomful of top angel investors and VCs.
As on the TechStars show, Demo Day is where each season will wrap. However, the new show aims to become a multi-season series, with plans to revisit the founders again after some time in a “where are they now?” type of segment.
Startups accepted into the program, which include anything from mobile apps to social discovery sites, will receive up to $20,000 in funding, space in Start Engine’s Westwood offices, educational seminars, mentoring sessions and access to investors.
Before, the TechStars companies may not have known they were defining a new genre of reality TV programming, but those inducted into Start Engine’s first class knew exactly what they were getting into. Though participation in the filming is optional, many have signed on precisely because of the exposure such a program will provide.
The new class includes the following companies:
¦BrandStand – Born at a BlackBerry hackathon in Boston, Co-founder Jason Hitchcock was motivated to join Start Engine after working in a Y-Combinator company and moved to L.A. the day before the program began. The app is a comparison voting service that measures consumer sentiment and allows users to promote their brand preferences. Players earn awards and prizes for their engagement by participating in location-based focus groups with their friends.
¦GonnaBe – This company is comprised of three advertising professionals who worked at national agencies including Made by Many (UK), DDB, McKinney, and Team One in El Segundo (where they met) on brands such as Lexus, Nationwide Insurance, Anheuser-Busch, Travelocity, Skype, AOL, Sherwin-Williams, Coldwell Banker, and Ritz-Carlton. GonnaBe is a social app connecting like-minded people based on interests, location and time. Users simply enter what they’re looking to do, when and where, and GonnaBe will show others looking for similar things, as well as deals that match their interests.
¦Hypemarks – Social discovery site that helps users find the best sites to check out, recommended by friends or people with similar interests. Users simply connect their social services at sign-up and Hypemarks will automatically curate activity and create recommendations through a stunning visual display for each user.
¦Outlisten – From three musicians founders, including one, Jeff Ponchick, who’s an ex-reality show editor, Outlisten is a mobile app and website for live concerts that creates a media memory of user recordings taken from their smartphones or digital cameras. Outlisten syncs multiple videos via waveform, creating an entirely new online concert experience.
¦PageWoo – This one comes from Co-founder Jason Crilly, an F-16 Crewchief for the Air Force who taught himself to code so he could build a social network for pickup basketball games in his neighborhood. His Co-founder, Holden, is also his wife, which should make for some interesting TV. PageWoo allows any user to create a marketing page for their product or service online without having to hire a developer or designer. Through PageWoo’s simple, streamlined interface, users can brand their pages with logos, upload files, add pictures, link all their social media and contact info, and then track visits, clicks and social sharing activity.
¦PROnoise – Community for independent musicians that helps them acquire fans, promote themselves, and sell their music. By establishing a highly interactive musical community that encourages viral sharing, PROnoise provides tools for emerging artists to make money and get attention.
¦Sandalbay Life – Founder Neil Malhotra was formerly Co-founder and CTO of Acclaim Games with Howard Marks, previously designed interplanetary trajectories at NASA JPL, and studied as a National Science Foundation Graduate Fellow at Caltech. SandalBay Life is a personal health and fitness platform that empowers consumers to know and manage their health through intelligent smartphone, tablet and web applications. The open interface integrates bio-sensor data from multiple sources, including wearable smart phone-connected devices, through Sandalbay’s API.
¦StretchE – Discount directory that publishes Groupon-like deals in the form of coupons for local merchants. StretchE.com provides businesses a sustainable way to attract local customers by offering coupons close to home and a loyalty program to foster customer retention.
¦thrdPlace – Web and mobile platform that enables members to create and support community projects. thrdPlace matches member needs with their community’s resources, helping them crowdsource funds, materials and labor and empowering them to impact their community.
One additional startup, which is currently in stealth mode, is creating a mobile platform that lets users instantly connect with everyone in their immediate vicinity.
The TV series will reportedly appear on a network first, then online afterwards, starting sometime in early 2012.
Update: Credit where credit is due. We’re hearing that Casey’s involvement was minimal, and that if anyone should get credit for TechStars’ production it should be Bloomberg’s Elizabeth Gould, the show’s producer. Casey reports he was in charge of hiring the crew and payroll, however. With regards to “executive producer” and “producer,” the bigger title isn’t always the bigger job.
-------------------------------------------------------------------
Lets face it this might be a perfect fit for Tony Cataldo. He already has the "Paul Kessler connection" in several areas, has reality show experience (see Danske Hollywoodfruer), and has been the top guy at about 10 different companies.
and no one knows more about "creative financing" at companies than Tony does.
and with his ride at GNBP in a questionable situation with his failing to file SEC 10Q, maybe this move to a Kessler controlled private company would be just the ticket for Mr. Wonderful. .
10Q now officially 4 weeks past due on its normal reporting date of 11-14-2012. It is 3 weeks and 2 days past due if including the 5 days given in 10QNT.
Tony Cataldo strikes again. Looks like there will be no "pony" here either.
Which will come first Tony Cataldo filing the GNBP 10Q or the Mayan calendar end of 12-21-2012?
Another record breaking day at GNBP closing at an all time low of $ .201.
So Tony Cataldo
Still no 10Q. Little wonder the sales
are at lower prices.
$ .24 is that a new low or was it $.211?
Bid up to two bits! 33,000 shares traded. Has Tony Cataldo been located!
On the other hand bid has dropped to 7 cents.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1282
|
Created
|
03/17/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |